To conduct and define the technical and programmatic requirements for a three-year, multi-institutional research and development effort to reverse engineer, characterize, manufacture, and evaluate…
Active Definitive Contract Awarded Last action
- Contract number
- 75F40126C00060
- Awardee
-
University Of Texas At Austin UEI V6AFQPN18437 Part of University Of Texas System
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $688,145
Award facts
- Opportunity
-
- FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Special Notice · FDABAA2600123 · Posted Nov 21, 2025
- Contract value 69% obligated
-
- $688,145.00 Current, with exercised options
- $990,864.00 Potential, with all options
- Completion date 2% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 257 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Takoma Park, MD 20901, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration awarded a $990,864 definitive contract to the University of Texas at Austin for a three-year research and development effort to reverse engineer, characterize, manufacture, and evaluate prototype long-acting poly(lactic-co-glycolic acid) formulations on September 30, 2026, under a firm fixed price structure with no set-aside.
The award derives from the FY26 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science, posted November 21, 2025, with a Stage One submittal deadline of February 24, 2026. The BAA solicits basic and applied research to advance FDA regulatory science across modernizing product development and evaluation, strengthening post-market surveillance, and enhancing public health preparedness. Place of performance is Takoma Park, MD. The period of performance extends through September 29, 2029.
Description
To conduct and define the technical and programmatic requirements for a three-year, multi-institutional research and development effort to reverse engineer, characterize, manufacture, and evaluate prototype long-acting poly(lactic-CO-glycolic acid)
Quick answers
Who was awarded contract 75F40126C00060?
75F40126C00060 was awarded to University Of Texas At Austin by Food and Drug Administration (Department of Health and Human Services) on September 30, 2026.
How much is contract 75F40126C00060 worth?
The government has obligated $688,145 on 75F40126C00060. Its potential value, with all options, is $990,864.
Was contract 75F40126C00060 competed?
The extent of competition for 75F40126C00060 was full and open competition. The government received 257 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award